8-K: Centessa Pharmaceuticals Clears HSR Antitrust Hurdle

Centessa Pharmaceuticals announced the expiration of the HSR Act waiting period, marking a key milestone in its acquisition by Eli Lilly.

Summary

• The Hart-Scott-Rodino (HSR) Act waiting period expired on May 21, 2026, satisfying a critical regulatory condition for the acquisition of Centessa Pharmaceuticals by Eli Lilly.
• The acquisition is structured as a court-sanctioned scheme of arrangement under the UK Companies Act of 2006.
• The transaction remains subject to remaining closing conditions, including shareholder approval and sanctioning by the High Court of Justice of England and Wales.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive, incremental step in the acquisition process, indicating that the deal is proceeding as planned without regulatory obstruction.

Positives

• Successful expiration of the HSR Act waiting period removes a significant regulatory barrier to the acquisition.
• The transaction continues to progress toward completion following the definitive agreement signed on March 31, 2026.

Negatives

• The acquisition remains subject to multiple outstanding conditions, including shareholder and court approvals, which carry inherent execution risks.

Risks

• Failure of shareholders to approve the acquisition.
• The High Court of Justice of England and Wales may decline to sanction the scheme of arrangement.
• Potential for competing acquisition proposals.
• Diversion of management attention from ongoing business operations.
• Risks associated with drug research, development, and commercialization timelines.
• Potential for legal proceedings related to the acquisition.

Future Outlook

The company is proceeding toward the closing of the acquisition, contingent upon shareholder approval and High Court sanctioning, though no specific closing date is guaranteed.

Management Comments

• Management emphasizes that shareholders should rely solely on the definitive proxy statement for voting decisions regarding the acquisition.

Industry Context

StockSavvy.ai notes that this development aligns with the broader trend of large-cap pharmaceutical companies like Eli Lilly aggressively acquiring specialized biotech firms to bolster their clinical pipelines.

Comparison to Industry Standards

• The use of a UK scheme of arrangement is a standard legal mechanism for cross-border acquisitions involving UK-incorporated entities.
• The HSR clearance process is consistent with standard regulatory timelines for pharmaceutical M&A activity.

Legal Proceedings

• The acquisition is subject to the sanctioning process of the High Court of Justice of England and Wales.

Stakeholder Impact

• Shareholders are advised to review the proxy statement to make informed voting decisions.
• Employees and business partners may face uncertainty regarding the integration process until the acquisition closes.

Next Steps

• Obtain shareholder approval for the acquisition.
• Secure sanctioning of the scheme of arrangement from the High Court of Justice of England and Wales.
• Deliver the court order to the Registrar of Companies in England and Wales.

Key Dates

Recommendation

The stock is currently trading in anticipation of the acquisition closing; investors should hold pending the final court and shareholder approvals.

Keywords

Centessa Pharmaceuticals, Eli Lilly, Acquisition, HSR Act, Merger, Biotech, CNTA